The role of T cells in rheumatoid arthritis: New subsets and new targets

Current Opinion in Rheumatology

Volumn 19, Issue 3, 2007, Pages 284-288

  Toh, Myew Ling ^a   Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Cytokines; Destruction; Inflammation; Rheumatoid arthritis; T cells; Treatment

Indexed keywords

ABATACEPT; CYTOKINE RECEPTOR ANTAGONIST; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; METHOTREXATE; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ANTIBODY;

AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; DRUG TARGETING; EFFECTOR CELL; HELPER CELL; HUMAN; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-17; MICE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 34247101156     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32805e87e0     Document Type: Review

References (33)

1. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-1132.
2. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Lett Nat 2006; 441:235-238. This study demonstrates an important role of TGF-β in Th17 development and the simultaneous induction of regulatory T cells.
3. Hoeve M, Savage N, de Boer T, et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006; 36:661-670. An in-vitro human model supporting the mouse studies that IL-23 is implicated in Th17 development and not Th1, and IL-12 in Th1 development and not Th17. Here, IL-23 induces and IL-12 inhibits IL-17 expression in human T cells.
4. Tan S, Zhao J, Bi C, et al. Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase C theta-deficient mice. J Immunol 2006; 176:2872-2879. A study in protein kinase C theta deficient mice demonstrating the regulatory effects of protein kinase C theta on IL-17 production in experimental autoimmune encephalomyelitis.
5. Healy A, Izmailova E, Fitzgerald M, et al. PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis. J Immunol 2006; 177:1886-1893. A study in protein kinase C theta deficient mice on the regulatory effects of protein kinase C theta in a mouse model of arthritis.
6. Toy D, Kugler D, Wolfson M, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006; 177:36-39. A key paper demonstrating that, in contrast to previous concepts, the functional IL-17R in the mouse is composed of two chains, IL-17RA and IL-17RC, which mediate IL-17A and IL-17F effects.
7. Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 2005; 52:2307-2312.
8. Koenders M, Lubberts E, van de Loo F, et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006; 176:6262-6269. An in-vivo mouse study demonstrating the dependence of IL-17 on TNF in early arthritis and the loss of this dependence in established disease.
9. + T cells in the K/BxN mouse model. Arthritis Rheum 2006; 54:492-498.
10. + T cells. J Exp Med 2006; 203:1459-1470. This paper demonstrates the role of IL-7-dependent homeostatic expansion of T cells in joint inflammation. IL-6 receptor gp130 mutant mice show a destructive arthritis only in the presence STAT3/IL-7-induced homeostatic proliferation.
11. + T cells in rheumatoid arthritis. Arthritis Rheum 2005; 52:3839-3849.
12. Miranda-Carus M, Benito-Miguel M, Balsa A, et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006; 54:1151-1164. A study demonstrating that T cells from RA patients will spontaneously induce osteoclastogenesis in monocytes.
13. Lee H, Jeon H, Song E, et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis evidence of NFκB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 2006; 54:1747-1758.
14. Sawai H, Park Y, Roberson J, et al. T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum 2005; 52:1392-1401.
15. + T cells and macrophages. Arthritis Rheum 2005; 52:1700-1710. IL-7, previously known to be implicated in T-cell differentiation, proliferation and survival, is shown to activate synovial T cells and macrophages.
16. Ponchel F, Verburg R, Bingham S, et al. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res Ther 2005; 7:R80-R92.
17. Morita Y, Gupta R, Seidl K, et al. Cytokine production by dendritic cells genetically engineered to express IL-4:induction of Th2 responses and differential regulation of IL-12 and IL-23 synthesis. J Gene Med 2005; 7:869-877.
18. + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140:360-367.
19. Ruprecht C, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3 regulatory T cells in inflamed synovia. J Exp Med 2005; 201:1793-1803.
20. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693-1700.
21. hi T-regulatory cells. Blood 2006; 108:253-261. This study suuports previous data that the efficacy of anti-TNF therapy in RA may be due to both direct anti-inflammatory effects and due to the restoration of normal regulatory T-cell function.
22. + regulatory T cells from nonobese diabetic mice. J Immunol 2005; 175:3053-3059.
23. + regulatory T cells. Arthritis Rheum 2005; 52:2212-2221.
24. Miellot A, Zhu R, Diem S, et al. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol 2005; 35:3704-3713.
25. + regulatory T cells. J Immunol 2006; 177:3806-3813. The identification of a new immunoregulatory T-cell subset induced by dendritic cell vaccination.
26. + T cells in rheumatoid arthritis. J Immunol 2005; 174:7292-7301.
27. Verburg R, Flierman R, Sont J, et al. Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Ann Rheum Dis 2005; 64:1397-1405.
28. Kremer J, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:2263-2271.
29. Genovese M, Becker J, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353:1114-1123.
30. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatercept in rheumatoid arthritis patients recieving background biologic and nonbiologic disease-modifying antirheumatic drugs. Arthritis Rheum 2006; 54:2807-2816.
31. Weinblatt M, Schiff M, Goldman A, et al. Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 2007; 66:228-234. A RA clinical trial of combination treatment with abatercept and etanercept demonstrating lack of better efficacy and increased side effects.
32. MacKenzie N. New therapeutics that treat rheumatoid arthritis by blocking T-cell activation. Drug Discov Today 2006; 11:952-956. A good review on emerging T-cell-targeted therapies.
33. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy results of a multicenter, randomized, double-blind, placebo-cntrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806.